Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.
What is the most Silicon Valley thing about your morning routine? Zoë, you go first. Zoë Schiffer: Pretty much the first ...
Me just dropped some major news in a tough year for the genetic testing company. After months of financial challenges, data ...
The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile ...
Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.
The firm expects to save more than $35 million in annualized costs through the restructuring. CEO Anne Wojcicki told ...
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0616 GMT – Mega Lifesciences is facing pressure from a ...